AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

COLL · NASDAQ · Drug Manufacturers - Specialty & Generic

Collegium Pharmaceutical

Commercializes ADHD and pain-management medicines across a U.S. prescription portfolio.

$25.35

After-hours close0.00 (0.00%)

At close$25.35(−4.12%)

Something off on this page? Send us feedback.

Profile

Collegium Pharmaceutical, Inc.COLLHealth Care

Sells branded prescription medicines in the United States for ADHD and moderate-to-severe pain, including JORNAY PM, AZSTARYS, BELBUCA, XTAMPZA ER, NUCYNTA, and SYMPROIC. Operates as one reportable segment, with recent acquisitions expanding the portfolio from responsible pain management into ADHD.

Commercializes a U.S. prescription portfolio split between ADHD and responsible pain management. Current products include JORNAY PM and AZSTARYS for ADHD, plus BELBUCA, XTAMPZA ER, NUCYNTA IR, NUCYNTA ER, and SYMPROIC across pain and opioid-related care.

Growth has been shaped by acquisitions rather than a broad research platform. BDSI added BELBUCA and SYMPROIC, Ironshore added JORNAY PM, and the Corium transaction added AZSTARYS after the latest audited fiscal year.

Operates as one reportable segment and manages the portfolio through consolidated commercial execution. Product demand is concentrated in the United States and depends on prescriber access, reimbursement, and controlled-substance rules covering methylphenidate, oxycodone, tapentadol, and buprenorphine.

Company facts

CEOVikram Karnani

ListedMay 7, 2015

ExchangeNASDAQ

HeadquartersStoughton, MA

CountryUnited States

Employees423

CIK0001267565

ISINUS19459J1043

Key statistics

Market cap$822.2M

EPS (ttm)$1.24

P/E (ttm)20.44

ROE16.0%

P/B2.64

P/S1.02

Dividend yield—

Beta0.38vs XLV 0.78

Year to date −44.3% · Average volume (30d) 667.1K

Analysts

Price target, next 12 months$48.00+89.3%Median of 12 analysts · vs the Aug 28 close

ConsensusBuy8 of 12 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $25.35

High$48.00+89.3%

Median$48.00+89.3%

Low$48.00+89.3%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 19, 2026	Barclays	Reiterate	Overweight	$56	$48
Feb 10, 2026	Truist Financial	Target		$55	$58
Jan 9, 2026	Barclays	Reiterate	Overweight	$58	$56
Jan 9, 2026	H.C. Wainwright	Target		$50	$60
Jan 7, 2026	Truist Financial	Target			$55

Earnings

EPS

Estimate$1.86

ReportedDue Nov 5, 2026

Revenue

Estimate$218.5M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	$1.72	$1.92	+11.6%	$199.6M	$199.9M	+0.1%	−18.55%
May 7, 2026Q1 FY26	$1.52	$1.76	+15.8%	$184.5M	$193.5M	+4.9%	−3.89%
Feb 26, 2026Q4 FY25	$2.14	$2.04	−4.7%	$206.4M	$205.4M	−0.4%	−5.77%
Nov 6, 2025Q3 FY25	$1.86	$2.25	+21.0%	$206.2M	$209.4M	+1.6%	+4.03%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$177.8M	$188.0M	$209.4M	$205.4M	$193.5M	$199.9M
Gross profit	$97.3M	$108.4M	$129.2M	$128.4M	$117.2M	$110.3M
Operating income	$21.7M	$35.1M	$63.6M	$59.2M	$32.0M	$3.7M
Net income	$2.4M	$12.0M	$31.5M	$17.0M	$14.5M	−$15.1M
Diluted EPS	$0.07	$0.34	$0.84	$0.46	$0.40	−$0.46
Gross margin	54.8%	57.7%	61.7%	62.5%	60.6%	55.2%
Operating margin	12.2%	18.7%	30.4%	28.8%	16.5%	1.9%

Fiscal years (4-quarter sums)FY21 $276.9M · FY22 $463.9M · FY23 $566.8M · FY24 $631.4M · FY25 $780.6M

Revenue by product · Q2 FY26

Belbuca$57.7M · 42%

Xtampza ER$45.0M · 33%

Nucynta ER$15.7M · 12%

Nucynta IR$14.4M · 11%

Symproic$3.0M · 2%

Balance sheet, Jun 30, 2026Cash & short-term investments $129.5M · Total debt $857.8M · Total assets $2.14B · Shareholders' equity $311.9M

Dividends

No dividends on record.

Ownership

Institutions 126.85%Insiders 3.53%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 32.43M · Float 32.05M · 98.8% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	5.44M	16.78%	13F	Aug 7, 2026
Jupiter Topco LLC	2.15M	6.62%	13F	Aug 14, 2026
Invesco Ltd.	1.88M	5.80%	13F	Aug 14, 2026
Janus Henderson Group PLC	1.83M	5.80%	13G	May 15, 2026
Integrated Core Strategies (US) LLC	1.77M	5.40%	13G	Aug 24, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
May 18, 2026	John Gordon Freund	director	−20	$34.05
May 15, 2026	John Gordon Freund	director	−4,127	$34.54
May 13, 2026	Nancy Lurker	director	−4,500	$35.97
May 11, 2026	Garen G. Bohlin	director	−8,700	$37.18
Mar 18, 2026	David Dieter	officer: EVP & General Counsel	−13,976	$34.92